STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI

Federal regulators convened private sector representatives and researchers for closed-door meetings aimed at facilitating the safe integration of clinical artificial intelligence (AI) into healthcare. At a July 8 "clinical AI demo day" at the Food and Drug Administration's (FDA) White Oak headquarters, officials from the FDA and Centers for Medicare and Medicaid Services (CMS) convened leaders from ten companies, according to materials reviewed by STAT.

The event provided a unique opportunity for federal health officials to gain firsthand insight into the state of AI technology currently utilized by healthcare providers. Representatives from four companies—Counsel Health, K Health, Hippocratic AI, and Ellipsis Health—shared their perspectives with the regulators, offering a direct perspective on the capabilities and limitations of current AI systems.

The gathering aimed to strike a balance between fostering innovation and ensuring regulatory oversight. By engaging with both established technology giants and emerging startups, the federal agencies sought to gather diverse viewpoints on the potential benefits and challenges of implementing AI solutions in clinical settings. This collaborative approach enables the regulators to better understand the intricacies of AI implementation and develop policies that promote responsible adoption while safeguarding patient safety and privacy.

The closed-door setting allowed the companies to freely discuss their experiences and insights with the regulators, facilitating a more transparent and informed dialogue. This exchange of information contributes to the ongoing efforts to establish regulatory frameworks that encourage the responsible use of AI in healthcare, while also addressing concerns surrounding cost-sharing and reimbursement mechanisms.